CD80

Withdrawn application: Orencia, 19/02/2024

Retrieved on: 
Mercredi, avril 3, 2024
CD86, Graft-versus-host disease, Gene, Methotrexate, Psoriasis, Letter, Cell, Bone marrow, Risk, Inflammation, Patient, Ageing, Psoriatic arthritis, HSCT, Allele, Joint, Protein, HLA, European Medicines Agency, Arthritis, Syringe, Rheumatism, Agency, Clinical trial, Skin, CD80, Cancer, Immune system, Blood, Calcineurin, Medicine, Vaccine

Withdrawn application: Orencia, 19/02/2024

Key Points: 


Withdrawn application: Orencia, 19/02/2024

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Urine, Medical Subject Headings, Diarrhea, Awareness, Marketing, Basiliximab, European Commission, INN, Leukopenia, Risk, Post-transplant lymphoproliferative disorder, Kidney transplantation, Infection, MPA, ATC, Pneumonia, Urinary tract infection, International, Gastroenteritis, Cytomegalovirus, Mycophenolic acid, Language, Pyelonephritis, Ciclosporin, CD86, Cancer, Basal-cell carcinoma, Transplant, Select, Committee, Patient, Human, Dehydration, Risk management, Anatomy, Medicine, Anemia, Vomiting, IIA, CHMP, CD80, Rejection, Dentistry

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 21, Status: Authorised

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Lundi, novembre 13, 2023
Biotechnology, Genetics, Health, Clinical Trials, Gene, Rheumatology, Patient, Inflammation, Synergy, Lupus, American College, CD28, SLE, ALPN, CD80, Alpine, ICOS, Autoimmunity, Immunoglobulin G, CD86, Pharmaceutical industry, Vaccine, Research

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • Acazicolcept target-related genes (ICOS, CD80, CD86) are upregulated in the T and B cells of SLE patients compared to healthy adults.
  • Acazicolcept reduces pathogenic hypergammaglobulinemia and glomerular IgG deposition in a mouse model of lupus.
  • Clinical investigation of acazicolcept for the treatment of SLE, such as in our ongoing phase 2 study, Synergy, continues to be supported.”

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development Presents major research results of birociclib, the start product, at the international stage in ASCO

Retrieved on: 
Jeudi, juin 8, 2023
Brain, Drug development, CDK6, Diabetes, American Society of Clinical Oncology, Stock exchange, Traffic barrier, Research, Sihuan Pharmaceutical, Drug design, Motherboard, ASCO, HKEX, Metabolism, Patient, Non-Euclidean geometry, The Company, R, CD80, CDK4, Society, III, Safety, Breast cancer, Pharmaceutical industry, Fine chemical

The excellent clinical results disclosed by Xuanzhu Biopharm at the ASCO annual meeting highlighted the development potential of birociclib.

Key Points: 
  • The excellent clinical results disclosed by Xuanzhu Biopharm at the ASCO annual meeting highlighted the development potential of birociclib.
  • We have over 40 medical aesthetics products and over 50 innovative drugs, many of which have already entered the harvesting stage.
  • Currently, Xuanzhu Biopharm has over 10 products approved to conduct clinical trials, and over 10 drug candidates in the preclinical development stage.
  • For more information about Sihuan Pharmaceutical, please visit the Company's website at https://www.sihuanpharm.com/
    Source: Sihuan Pharmaceutical Holdings Group Ltd.

Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023

Retrieved on: 
Mardi, avril 18, 2023
AACR, CD86, American Association for Cancer Research, CCR8, Doctor of Philosophy, CD8, Patient, Poster, CD80, Tumor microenvironment, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.

Key Points: 
  • CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida.
  • The data will be presented in a poster session (abstract #5125) being held today.
  • Anti-CCR8 and anti-PD-1 combination therapy increased tumor immune cell infiltration, cytokine production and improved overall survival in a checkpoint inhibitor resistant melanoma model.
  • A copy of the poster will be available on the Posters & Publications page of the company’s website following the presentation.

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Retrieved on: 
Lundi, avril 17, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, AACR, Half-life, CD28, CD3, CD86, Cancer, ENPP3, American Association for Cancer Research, TACSTD2, Antibody, CEACAM5, TCR, STEAP1, CD80, Cytokine, Tumor microenvironment, Vaccine

The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Key Points: 
  • The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
  • T cells in the tumor microenvironment require engagement of both their T cell receptor (TCR) and their co-stimulatory receptors, like CD28, to achieve full activation.
  • Xencor has developed a modular XmAb® bispecific antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement.
  • “We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets.”

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Lundi, novembre 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Paclitaxel, Review, Coronavirus, Society, SEC, TAM, Risk, NYSE, Drug discovery, Immunotherapy, Biopharmaceutical, Securities Exchange Act of 1934, Securities Act of 1933, Tumor-associated macrophage, CD86, Disease, SITC, Forward-looking statement, Abstract, NYSE American, Neoplasm, Convention center, History, CD163, Technetium-99m, Boston Convention and Exhibition Center, Investigational New Drug, Health, Decision-making, Phenotype, Toxicity, CD80, Wound healing, Research, Annual report, Macrophage, Pharmaceutical industry, Cancer

The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.

Key Points: 
  • The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.
  • These details were embargoed by SITC until the week of the meeting.
  • Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home .
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Vendredi, octobre 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research

Retrieved on: 
Vendredi, octobre 7, 2022
Quality of life, Merck, List of health departments and ministries, Sale, Kerala State Drugs and Pharmaceuticals Limited, Patient, Dostarlimab, BIS, GlaxoSmithKline, Pembrolizumab, Colorectal cancer, BTC, Report, Center for Urban and Regional Analysis, TRADD, PD-1, Research, Adult, Patent, FREE, Ministry, Cisplatin, CD80, Name, Bristol Myers Squibb, Medical device, Pharmaceutical industry, Palladium, Health

FREMONT, Calif., Oct. 7, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled  PD-1/PDL-1 Inhibitor Market – A Global and Regional Analysis. 

Key Points: 
  • More and more research activities are taking place in order to maximize the therapeutic potential of PD-1/PDL-1 inhibitors and great results have been demonstrated as well."
  • In September 2022, Merck's anti-PD-1 therapy KEYTRUDA received four new approvals from Japan's Ministry of Health, Labor and Welfare.
  • Keytruda is also the first product approved under the PD-1/PDL-1 inhibitor category of immune checkpoint inhibitors and has a patent valid till 2028.
  • BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscape.

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Mercredi, octobre 5, 2022
Molecule, SAN, News, U.S. Securities and Exchange Commission, Murinae, HS, SEC, PD, Achievement, SITC, ANCA, Degenerative disease, Annual report, Patient, Security (finance), Annual general meeting, Immunotherapy, Medication, Nasdaq, Small molecule, Cancer, Private Securities Litigation Reform Act, Hidradenitis suppurativa, Goal, Company, Society, PD-1, Adult, Safety, GLOBE, Full, PK, CD80, Terminology, PD-L1, Society for Immunotherapy of Cancer, Risk, Pharmaceutical industry, Vaccine, Neoplasm

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA.

Key Points: 
  • Preclinical characterization has demonstrated that CCX559 blocks binding to PD-1 and CD80, and prevents PD-L1 inhibition of T cell activation.
  • CCX559, when orally administered in animal models, demonstrated anti-tumor efficacy, including the ability to induce complete responses.
  • The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells.
  • ChemoCentryxis also developing CCX559, a highly potent orally administered small molecule PD-L1 checkpoint inhibitor, for the treatment of patients with solid tumors.